Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LY 2874455

Next Previous
X
Search
Drug Profile

LY 2874455

Alternative Names: FGF receptor inhibitor - Eli Lilly and Company; LY-2874455; pan-FGFR inhibitor - Eli Lilly and Company

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type 4 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cancer
  • No development reported Acute myeloid leukaemia

Most Recent Events

  • 28 Sep 2020 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy, Second-line therapy or greater) in USA (PO)
  • 01 Jun 2020 Eli Lilly and Company completes a phase I clinical trial in Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT03125239)
  • 28 Jan 2018 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (PO, Capsule)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top